Biotech Updates

U.S. FDA Approves First Experimental Zika Vaccine for Clinical Trials

June 22, 2016

The U.S. Food and Drug Administration (US FDA) approved the clinical trial of an experimental vaccine for Zika virus for the first time. The first experimental vaccine for Zika was developed by Inovio. The initial results of the trial, which will involve 40 adults, are expected to come out later this year.

The vaccine developed by Inovio with a working name of GLS-5700 is a DNA vaccine. When injected, it involves coding of DNA to produce the protein that surrounds the Zika virus. Electrical pulse is applied to the site of injection to help the DNA locate the cells. Then the cells teach the immune system to detect Zika virus as a foreign invader, producing antibodies to combat the virus.

Read the original article from Stat News.